# US 2021/0330820 A1 · Nanoemulsion of iodinated fatty acids for ct imaging > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330820 A1 - Document ID: US20210330820A1 - Status: Published application - Kind: A1 - Application number: 16/637,366 - Filed: 2018-07-27 - Published: 2021-10-28 - Earliest claimed: 2017-08-07 - Assignees: University of Geneva - Applicants: University of Geneva - Inventors: Laurent VINET; Andrej BABIC; Eric ALLEMANN - Web page: https://patentgrep.com/patent/US20210330820A1 ## CPC - A61K 49/0438: {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions} - A61K 49/0461: {Dispersions, colloids, emulsions or suspensions} - B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES ## Abstract An iodinated CT contrast agent made of fatty acid derivatives for non-invasive visualisation and quantification of the brown and/or beige adipose tissue (BAT) or for imaging the heart and/or liver of a subject, to be taken orally which is a breakthrough in CT imaging. Image resolution by CT is significantly enhanced compared to PET. ## Claims ### Claim at position 1 1-20. (canceled) ### Claim 21 A method of in vivo imaging with Computed Tomography brown and/or beige adipose tissue (BAT) in a subject, comprising administering orally a contrast agent comprising iodinated fatty acids having 4 to 24 carbon atoms and/or esters and/or salts and/or mixtures thereof according to general formula I: wherein n=2-22; R1 is H or I, with the provisions that the number of iodine atoms is 1 to 6, and that the iodine atoms are neither geminal nor vicinal; and where R2 is H, unsaturated or saturated, linear or branched alkyls, alkyls, alkoxyalkyl, hydroxyalkoxyalkyl, polyhydroxyalkyl, hydroxy poly alkyleneoxyalkyl. ### Claim 22 (depends on 21) The method of in vivo imaging with CT according to claim 21, wherein the iodinated fatty acids having 4 to 24 carbon atoms and/or esters and/or salts and/or mixtures thereof according to general formula I is in the form of a biocompatible nano-emulsion. ### Claim 23 (depends on 21) The method of in vivo imaging with CT according to claim 21, wherein the contrast agent is adapted for non-invasive in vivo imaging, quantification, and/or monitoring of the activity of the brown and/or beige adipose tissue (BAT) in said subject. ### Claim 24 (depends on 22) The method of in vivo imaging with CT according to claim 22, wherein the contrast agent consists in a biocompatible nano-emulsion of iodinated fatty acids having 10 to 20 carbon atoms according to general formula I. ### Claim 25 (depends on 22) The method of in vivo imaging with CT according to claim 22, wherein the contrast agent consists in a biocompatible nano-emulsion of iodinated fatty acids having 16 to 18 carbon atoms according to general formula I. ### Claim 26 (depends on 21) The method of in vivo imaging with CT according to claim 21, wherein the iodinated fatty acid is an iodinated linolenic acid. ### Claim 27 (depends on 22) The method of in vivo imaging with CT according to claim 22, wherein the nano-emulsion comprises biocompatible emulsifiers selected among lecithin, polyethylene glycol ethers with fatty alcohols, polysorbates and sorbitan esters or their mixtures. ### Claim 28 (depends on 27) The method of in vivo imaging with CT according to claim 27, wherein the amount of said biocompatible emulsifiers in the nano-emulsion is between 5-30% (w/w) of the total nano-emulsion. ### Claim 29 (depends on 21) The method of in vivo imaging with CT according to claim 21, wherein the peroral CT contrast agent is administrated at a dose corresponding to between 0.5 and 1.6 mg of iodine per gram of body weight. ### Claim 30 A method of in vivo imaging with Computed Tomography the heart in a subject, comprising administering orally a contrast agent comprising iodinated fatty acids having 4 to 24 carbon atoms and/or esters and/or salts and/or mixtures thereof according to general formula I: wherein n=2-22; R1 is H or I, with the provisions that the number of iodine atoms is 1 to 6, and that the iodine atoms are neither geminal nor vicinal; and where R2 is H, unsaturated or saturated, linear or branched alkyls, alkyls, alkoxyalkyl, hydroxyalkoxyalkyl, polyhydroxyalkyl, hydroxy poly alkyleneoxyalkyl. ### Claim 31 (depends on 30) The method of in vivo imaging with CT according to claim 30, wherein the iodinated fatty acids having 4 to 24 carbon atoms and/or esters and/or salts and/or mixtures thereof according to general formula I is in the form of a biocompatible nano-emulsion. ### Claim 32 (depends on 31) The method of in vivo imaging with CT according to claim 31, wherein the contrast agent consists in a biocompatible nano-emulsion of iodinated fatty acids having 16 to 18 carbon atoms according to general formula I. ### Claim 33 (depends on 30) The method of in vivo imaging with CT according to claim 30, wherein the iodinated fatty acid is an iodinated linolenic acid. ### Claim 34 (depends on 30) The method of in vivo imaging with CT according to claim 30, wherein the contrast agent is for the visualization of the heart and evaluation of its function in said subject. ### Claim 35 (depends on 30) The method of in vivo imaging with CT according to claim 30, wherein the peroral CT contrast agent is administrated at a dose corresponding to between 0.5 and 1.6 mg of iodine per gram of body weight.